Lv5
1250 积分 2020-09-26 加入
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
6天前
已完结
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma
10天前
已完结
结直肠癌化疗合理用药原则专家共识
2个月前
已完结
The role of neoadjuvant chemotherapy in ovarian cancer
3个月前
已完结
CA-125 elimination rate constant K (KELIM) as a promising predictor of complete cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer patients: a retrospective study from two Chinese hospitals
3个月前
已完结
Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer
3个月前
已完结
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
3个月前
已完结
A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial
5个月前
已完结
Vulnerable Older Adults With Ovarian Cancer—Time to Stop Undertreating
5个月前
已完结
Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer
6个月前
已完结
皖公网安备34019202002308
